Cardiff Oncology Other 8-K Filing
Cardiff Oncology stockholders approved an amendment to the company's Certificate of Incorporation to double the number of authorized shares of common stock from 150 million to 300 million. The vote took place at a Special Meeting on October 22, 2026, with approximately 78% of voted shares in favor. This increase in authorized capital provides the company with additional shares for future corporate purposes, such as financing or strategic transactions.